Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).
about
Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor Simeprevir and frequently used concomitant medications.Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents
P2860
Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Simeprevir in combination with ...... bel, single-arm study (PLUTO).
@en
Simeprevir in combination with ...... bel, single-arm study (PLUTO).
@nl
type
label
Simeprevir in combination with ...... bel, single-arm study (PLUTO).
@en
Simeprevir in combination with ...... bel, single-arm study (PLUTO).
@nl
prefLabel
Simeprevir in combination with ...... bel, single-arm study (PLUTO).
@en
Simeprevir in combination with ...... bel, single-arm study (PLUTO).
@nl
P2093
P2860
P50
P356
P1476
Simeprevir in combination with ...... abel, single-arm study (PLUTO)
@en
P2093
F G Rodríguez
J M Pascasio
R Kalmeijer
P2860
P304
P356
10.1111/APT.13883
P407
P577
2016-11-29T00:00:00Z